R&D channel feed

As­traZeneca’s Imfinzi/treme com­bo strikes out — again — in lung can­cer. Is it time for last rites?

6 years ago
Pharma

FDA de­ci­sion on Ver­tex's CF triple will come just ahead of planned CEO shake­up

6 years ago
FDA+

An MIT spin­out kills one of its ‘liv­ing ther­a­peu­tics’ af­ter flunk­ing an ear­ly-stage study — shares rout­ed

6 years ago

As­traZeneca's di­a­betes drug Farx­i­ga helps pa­tients with heart dis­ease and with­out di­a­betes in land­mark tri­al

6 years ago
Pharma

Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

6 years ago
FDA+

No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

6 years ago
Pharma

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

6 years ago

Mi­nor­i­ty racial groups con­tin­ue to be dis­mal­ly rep­re­sent­ed in can­cer tri­als — study

6 years ago

Van­da shares slide af­ter FDA spurns their big end­point and re­jects a pitch on jet lag re­lief

6 years ago

Ab­b­Vie gets its FDA OK for JAK in­hibitor upadac­i­tinib, but don’t look for this one to hit ex­ecs’ lofty ex­pec­ta­tions

6 years ago

The key dates for KRAS watch­ers through the end of the year — the trail is nar­row and risks are ex­treme

6 years ago

Watch out Bay­er, Roche is com­ing for you with a dis­count price ri­val to the tu­mor ag­nos­tic drug you got from Loxo

6 years ago

Re­gen­eron puts fin­ish­ing touch­es on $800M ex­pan­sion project close to home

6 years ago

A PARP suc­ces­sor? Michi­gan aca­d­e­m­ic team touts po­ten­tial of an ag­ing — but still ex­per­i­men­tal — As­traZeneca drug in DNA dam­age re­pair

6 years ago

Ail­ing Mallinck­rodt's drug for rare, life-threat­en­ing re­nal con­di­tion clears piv­otal study

6 years ago
Pharma

FDA en­dors­es new reg­i­men for dead­ly drug-re­sis­tant tu­ber­cu­lo­sis ram­pant in de­vel­op­ing world

6 years ago
Pharma
FDA+

The re­al-world ev­i­dence project at the FDA adds Syapse to its list of part­ners in a push past tri­al bound­aries

6 years ago
FDA+

Macro­Gen­ics vs Mer­ck: An un­der­dog plans a pre­mier bout with the heavy­weight cham­pi­on of the PD-1 class

6 years ago

Armed with stel­lar — if niche — PhI­II da­ta, Re­gen­eron steers 'break­through' cho­les­terol drug to post-PC­SK9 wa­ters

6 years ago

Eli Lil­ly's Taltz beats J&J's Trem­fya in pso­ri­a­sis head-to-head — but the mar­ket­ing brawl is just be­gin­ning

6 years ago
Pharma

Biotech tar­get­ing rare heart mu­ta­tion with gene ther­a­py scores $11M in Se­ries A haul

6 years ago
Financing
Startups

As­traZeneca's jug­ger­naut PARP play­er Lyn­parza scoops up an­oth­er dom­i­nant win in PhI­II as the FDA adds a 'break­through' for Calquence

6 years ago
Pharma

No­var­tis of­floads a late-stage PI3Kẟ rare dis­ease pro­gram in a dis­count deal

6 years ago
Deals

Lit­tle De­ci­phera will hus­tle pos­i­tive PhI­II sur­vival da­ta on lead can­cer drug to the FDA in search of its first OK — shares soar

6 years ago
First page Previous page 235236237238239240241 Next page Last page
A service from the Financial Times